{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:47:09Z","timestamp":1789775229746,"version":"4.0.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>While Janus kinase inhibitors (JAKi) have been associated with an increased risk of serious infections compared with biologics in patients with ulcerative colitis (UC), data comparing the risk of infection across individual JAKi remain limited. We aimed to compare the risk of serious infections among patients with UC treated with tofacitinib, upadacitinib, or filgotinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a nationwide cohort study using the French National Health Data System, including UC patients aged &amp;gt;15\u2009years who initiated tofacitinib, upadacitinib, or filgotinib between 2019 and 2025. We assessed the risk of serious infection (defined as requiring hospitalization) according to treatment exposure. Propensity score weighting accounted for indication bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 237 serious infections occurred among 6449 JAKi initiations: 2735 used upadacitinib, 2825 tofacitinib, and 889 filgotinib. Median age was 39\u2009years, 49.5% were women, and median time since UC diagnosis was 7.1\u2009years. Incidence rates per 1000 patient-years were 38.8 for upadacitinib, 30.6 for tofacitinib, and 28.4 for filgotinib. Compared with upadacitinib, adjusted hazard ratios for serious infection were 0.93 (95% CI: 0.70-1.24) for tofacitinib and 0.88 (95% CI: 0.56\u20131.39) for filgotinib. No differences were observed across infection sites or pathogen types. Higher doses of upadacitinib and tofacitinib were associated with increased infection risk. The risk of non-severe infections, particularly against herpes simplex virus and varicella zoster virus, was highest with upadacitinib and lowest with filgotinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tofacitinib, upadacitinib, and filgotinib were associated with similar risks of serious infection in patients with UC. Infection risk appeared to be driven primarily by dose rather than by type of JAKi.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag053","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:45:57Z","timestamp":1775216757000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparative risk of serious infection in patients with ulcerative colitis treated with JAK inhibitors"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1156-9289","authenticated-orcid":false,"given":"Antoine","family":"Meyer","sequence":"first","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Bic\u00eatre, Assistance Publique-H\u00f4pitaux de Paris, Paris-Saclay , Le Kremlin Bic\u00eatre,","place":["France"]},{"name":"Universit\u00e9 Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP , Villejuif,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Bertrand","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Bic\u00eatre, Assistance Publique-H\u00f4pitaux de Paris, Paris-Saclay , Le Kremlin Bic\u00eatre,","place":["France"]},{"name":"Universit\u00e9 Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP , Villejuif,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Martin","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Bic\u00eatre, Assistance Publique-H\u00f4pitaux de Paris, Paris-Saclay , Le Kremlin Bic\u00eatre,","place":["France"]},{"name":"Universit\u00e9 Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP , Villejuif,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Bic\u00eatre, Assistance Publique-H\u00f4pitaux de Paris, Paris-Saclay , Le Kremlin Bic\u00eatre,","place":["France"]},{"name":"Universit\u00e9 Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP , Villejuif,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-1222","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Amiot","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Bic\u00eatre, Assistance Publique-H\u00f4pitaux de Paris, Paris-Saclay , Le Kremlin Bic\u00eatre,","place":["France"]},{"name":"Universit\u00e9 Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP , Villejuif,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"2026051203180067100_jjag053-B1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/apt.70209","article-title":"Network meta-analysis: efficacy of biological therapies and small molecules as maintenance therapy in ulcerative colitis","volume":"62","author":"Barberio","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026051203180067100_jjag053-B2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2026051203180067100_jjag053-B3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"2026051203180067100_jjag053-B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2026.04.015","article-title":"Serious infection in inflammatory bowel diseases patients treated with vedolizumab, ustekinumab, JAK inhibitors, anti-TNF or aminosalicylates","author":"Bertrand","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026051203180067100_jjag053-B5","doi-asserted-by":"publisher","first-page":"jjaf229","DOI":"10.1093\/ecco-jcc\/jjaf229","article-title":"Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: a nationwide cohort study","volume":"20","author":"Axelrad","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026051203180067100_jjag053-B6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"2026051203180067100_jjag053-B7","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.cgh.2025.06.041","article-title":"Comparative safety of janus kinase inhibitors vs tumor necrosis factor antagonists in patients with inflammatory bowel diseases","volume":"24","author":"Ahuja","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026051203180067100_jjag053-B8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000546640","article-title":"Efficacy and safety of three janus kinase inhibitors in ulcerative colitis patients over and under 65 years of age: a real-world comparative analysis","volume":"10","author":"Akiyama","year":"2025","journal-title":"Inflamm Intest Dis"},{"key":"2026051203180067100_jjag053-B9","doi-asserted-by":"publisher","first-page":"i1992","DOI":"10.1093\/ecco-jcc\/jjae190.1258","article-title":"Safety of tofacitinib and upadacitinib compared to other advanced therapies in ulcerative colitis: a large real-world comparison","volume":"19","author":"Fiorino","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026051203180067100_jjag053-B10","doi-asserted-by":"publisher","first-page":"e2531204","DOI":"10.1001\/jamanetworkopen.2025.31204","article-title":"Comparative safety of JAK inhibitors vs TNF Antagonists in immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"8","author":"Solitano","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026051203180067100_jjag053-B11","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65 Suppl 4","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique."},{"key":"2026051203180067100_jjag053-B12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"2026051203180067100_jjag053-B13","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.cgh.2021.07.028","article-title":"Serious infections in children born to mothers with inflammatory bowel disease with in utero exposure to thiopurines and anti-tumor necrosis factor","volume":"20","author":"Meyer","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026051203180067100_jjag053-B14","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2026051203180067100_jjag053-B15","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s11606-013-2755-z","article-title":"Six persistent research misconceptions","volume":"29","author":"Rothman","year":"2014","journal-title":"J Gen Intern Med"},{"key":"2026051203180067100_jjag053-B16","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/art.42547","article-title":"Differences in JAK isoform selectivity among different types of JAK inhibitors evaluated for rheumatic diseases through in vitro profiling","volume":"75","author":"Virtanen","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"2026051203180067100_jjag053-B17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"2026051203180067100_jjag053-B18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/pds.4006","article-title":"Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database","volume":"25","author":"Sahli","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/5\/jjag053\/68270902\/jjag053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/5\/jjag053\/68270902\/jjag053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:18:07Z","timestamp":1778570287000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag053\/8676233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag053","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"jjag053"}}